Biovian to attend New Horizons in Bioprocessing conference, Stockholm
Press Release | Biovian Ltd
DECEMBER 01, 2014
Turku, Finland: – Biopharmaceutical CMO Biovian announced today it would attend the upcoming one day New Horizons in Bioprocessing conference in Stockholm.
Biovian’s Director of Business Development and Projects, Mr. Antti Nieminen, will be available for face-to-face discussions with delegates at the event.
The New Horizons in Bioprocessing event will be held at Stockholm’s Waterfront Congress Center on December 11, 2014.
Organised by Kemivärlden Biotech and Pall Life Sciences, the conference will focus on Single Use manufacturing technologies for the future, and will consider, developments, new directions, management and business areas of bio-processing with focus on technical rather than commercial achievements.
Morten Munk of CMC Biologics A/S will moderate the conference. The agenda features discussion on analytical techniques, cell culture and upstream processing, downstream processing and single-use systems, with presentations on disposable technologies, high efficiency continuous chromatography system, single-use mixing technologies and diaphragm valves for sterile application, microfluidics capillary electrophoresis for protein characterization, modulation of N-linked glycosylation profiles and outsourcing of complex manufacturing processes.
End-to-end GMP services
“I’m very much looking forward to this conference,” said Mr. Nieminen.
“I will be able to talk to visitors about latest developments in Biovian’s distinctive “gene to finished vial“ end-to-end GMP service as well as biopharma process developmentor manufacturing projects that require the our extensive range of cGMP manufacturing and development services,” he added.
Biovian Ltd. is a one-stop-shop Contract Manufacturing Organization (CMO) specializing in full-process development and manufacture that extends ‘from gene to finished vial’.
Biovian offers Good Manufacturing Practice compliant (cGMP) services from its 2,300 square meter facilities in Turku, Finland, that are EMA and FDA certified for production of investigational and commercial products.
The CMO has more than a decade’s successful track record in pharmaceutical contract manufacturing ranging over a wide variety of different biopharmaceutical projects. Biovian GMP services include microbial fermentation, mammalian cell culture, viral vector production, protein purification, formulation, aseptic fill & finish, analytical quality control, stability studies and cell banking. It also offers labeling, packaging, storage and QP release services.
Biovian also provides development services that cover cell line, process and analysis.
Name: Dr. Knut Ringbom, CEO, Biovian Ltd.
Tel: +35 82 274 8877
Click on Biovian to attend New Horizons in Bioprocessing conference, Stockholm for other information.
Click on Biovian to contact the company directly.